Skip to main content
Top
Published in: Journal of Anesthesia 5/2018

01-10-2018 | Original Article

Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models

Authors: Kenichi Masui, Sayaka Ishigaki, Atsuko Tomita, Hiroshi Otake

Published in: Journal of Anesthesia | Issue 5/2018

Login to get access

Abstract

Purpose

Equilibration rate constant is necessary to calculate effect-site concentration, which is useful to control drug effect. We developed pharmacodynamic models for published five compartmental pharmacokinetic models published by Wierda, Szenohradszky, Cooper, Alvarez-Gomez, and McCoy.

Methods

We used 3848 train-of-four ratios from 15 male and nine female patients (21–76 years; 44–93 kg body weight; 148–181 cm height; and 17.3–29.8 kg/m2 body mass index) as pharmacodynamic measures, which were collected at the start of 0.6 mg/kg rocuronium administration until the end of the surgery. Effect compartment was assumed to be connected to central compartment of the pharmacokinetic model with equilibration rate constant (ke0). Sigmoid Emax model was fitted to describe the relationship between train-of-four ratio and effect-site concentration. Age, sex, and body mass index were assessed as possible covariates of the following model parameters: ke0, effect-site concentration for half of maximum effect, and the steepness of the effect-site concentration versus effect relationship.

Results

The duration of neuromuscular monitoring was 69 (37–129) [median (range)] min. All pharmacodynamic models included age and three included sex as significant covariates. Ke0 values ranged between 0.0820 and 0.247 depending on the pharmacokinetic model. The time-courses of the effect-site concentration were similar among the pharmacodynamic models for Wierda, Cooper, and Alvarez-Gomez pharmacokinetic models, which were lower than that for the Szenohradszky pharmacokinetic model.

Conclusion

Each pharmacodynamic model with the corresponding pharmacokinetic model can be described the time course of rocuronium effect appropriately. The required effect-site concentration of rocuronium for a pharmacodynamic effect was depending on the applied models.
Literature
1.
go back to reference Proost JH. Pharmacokinetic–pharmacodynamic modelling of anesthetic drugs. In: Absalom AR, Mason KP (eds) Total intravenous anesthesia and target controlled infusions: a comprehensive global anthology. Cham: Springer; 2017. pp 117–45.CrossRef Proost JH. Pharmacokinetic–pharmacodynamic modelling of anesthetic drugs. In: Absalom AR, Mason KP (eds) Total intravenous anesthesia and target controlled infusions: a comprehensive global anthology. Cham: Springer; 2017. pp 117–45.CrossRef
2.
go back to reference Glen JB, Engbers FHM. The influence of target concentration, equilibration rate constant (ke0) and pharmacokinetic model on the initial propofol dose delivered in effect-site target-controlled infusion. Anaesthesia. 2016;71:306–14.CrossRef Glen JB, Engbers FHM. The influence of target concentration, equilibration rate constant (ke0) and pharmacokinetic model on the initial propofol dose delivered in effect-site target-controlled infusion. Anaesthesia. 2016;71:306–14.CrossRef
3.
go back to reference Minto CF, Schnider TW, Gregg KM, Henthorn TK, Shafer SL. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology. 2003;99:324–33.CrossRef Minto CF, Schnider TW, Gregg KM, Henthorn TK, Shafer SL. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics. Anesthesiology. 2003;99:324–33.CrossRef
4.
go back to reference Wierda JM, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth. 1991;38:430–5.CrossRef Wierda JM, Kleef UW, Lambalk LM, Kloppenburg WD, Agoston S. The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth. 1991;38:430–5.CrossRef
5.
go back to reference Szenohradszky J, Fisher DM, Segredo V, Caldwell JE, Bragg P, Sharma ML, Gruenke LD, Miller RD. Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology. 1992;77:899–904.CrossRef Szenohradszky J, Fisher DM, Segredo V, Caldwell JE, Bragg P, Sharma ML, Gruenke LD, Miller RD. Pharmacokinetics of rocuronium bromide (ORG 9426) in patients with normal renal function or patients undergoing cadaver renal transplantation. Anesthesiology. 1992;77:899–904.CrossRef
6.
go back to reference Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth. 1993;71:222–6.CrossRef Cooper RA, Maddineni VR, Mirakhur RK, Wierda JM, Brady M, Fitzpatrick KT. Time course of neuromuscular effects and pharmacokinetics of rocuronium bromide (Org 9426) during isoflurane anaesthesia in patients with and without renal failure. Br J Anaesth. 1993;71:222–6.CrossRef
7.
go back to reference Alvarez-Gomez JA, Estelles ME, Fabregat J, Perez F, Brugger AJ. Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. Eur J Anaesthesiol Suppl. 1994;9:53–6.PubMed Alvarez-Gomez JA, Estelles ME, Fabregat J, Perez F, Brugger AJ. Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. Eur J Anaesthesiol Suppl. 1994;9:53–6.PubMed
8.
go back to reference McCoy EP, Mirakhur RK, Maddineni VR, Wierda JM, Proost JH. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth. 1996;76:29–33.CrossRef McCoy EP, Mirakhur RK, Maddineni VR, Wierda JM, Proost JH. Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia. Br J Anaesth. 1996;76:29–33.CrossRef
9.
go back to reference Kleijn HJ, Zollinger DP, van den Heuvel MW, Kerbusch T. Population pharmacokinetic–pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. Br J Clin Pharmacol. 2011;72:415–33.CrossRef Kleijn HJ, Zollinger DP, van den Heuvel MW, Kerbusch T. Population pharmacokinetic–pharmacodynamic analysis for sugammadex-mediated reversal of rocuronium-induced neuromuscular blockade. Br J Clin Pharmacol. 2011;72:415–33.CrossRef
10.
go back to reference Vermeyen KM, Hoffmann VL, Saldien V. Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model. Br J Anaesth. 2003;90:183–8.CrossRef Vermeyen KM, Hoffmann VL, Saldien V. Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model. Br J Anaesth. 2003;90:183–8.CrossRef
11.
go back to reference Plaud B, Proost JH, Wierda JM, Barre J, Debaene B, Meistelman C. Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. Clin Pharmacol Ther. 1995;58:185–91.CrossRef Plaud B, Proost JH, Wierda JM, Barre J, Debaene B, Meistelman C. Pharmacokinetics and pharmacodynamics of rocuronium at the vocal cords and the adductor pollicis in humans. Clin Pharmacol Ther. 1995;58:185–91.CrossRef
12.
go back to reference Ishigaki S, Masui K, Kazama T. Saline flush after rocuronium bolus reduces onset time and prolongs duration of effect: a randomized clinical trial. Anesth Analg. 2016;122:706–11.CrossRef Ishigaki S, Masui K, Kazama T. Saline flush after rocuronium bolus reduces onset time and prolongs duration of effect: a randomized clinical trial. Anesth Analg. 2016;122:706–11.CrossRef
13.
go back to reference Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789–808.CrossRef Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand. 2007;51:789–808.CrossRef
14.
go back to reference Masui K. How to select a PK/PD model. In: Absalom AR, Mason KP (eds) Total intravenous anesthesia and target controlled infusions: a comprehensive global anthology. Cham: Springer. 2017. pp 171–87.CrossRef Masui K. How to select a PK/PD model. In: Absalom AR, Mason KP (eds) Total intravenous anesthesia and target controlled infusions: a comprehensive global anthology. Cham: Springer. 2017. pp 171–87.CrossRef
15.
go back to reference Furuya T, Suzuki T, Kashiwai A, Konishi J, Aono M, Hirose N, Kato J, Ogawa S. The effects of age on maintenance of intense neuromuscular block with rocuronium. Acta Anaesthesiol Scand. 2012;56:236–9.CrossRef Furuya T, Suzuki T, Kashiwai A, Konishi J, Aono M, Hirose N, Kato J, Ogawa S. The effects of age on maintenance of intense neuromuscular block with rocuronium. Acta Anaesthesiol Scand. 2012;56:236–9.CrossRef
16.
go back to reference Baykara N, Şahin T, Alpar R, Solak M, Toker K. Evaluation of intense neuromuscular blockade caused by rocuronium using posttetanic count in male and female patients. J Clin Anesth. 2003;15:446–50.CrossRef Baykara N, Şahin T, Alpar R, Solak M, Toker K. Evaluation of intense neuromuscular blockade caused by rocuronium using posttetanic count in male and female patients. J Clin Anesth. 2003;15:446–50.CrossRef
17.
go back to reference Xue FS, Tong SY, Liao X, Liu JH, An G, Luo LK. Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Anesth Analg. 1997;85:667–71.CrossRef Xue FS, Tong SY, Liao X, Liu JH, An G, Luo LK. Dose-response and time course of effect of rocuronium in male and female anesthetized patients. Anesth Analg. 1997;85:667–71.CrossRef
18.
go back to reference Sasakawa T, Masui K, Kazama T, Iwasaki H. The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen. J Anesth. 2016;30:620–7.CrossRef Sasakawa T, Masui K, Kazama T, Iwasaki H. The predictive ability of six pharmacokinetic models of rocuronium developed using a single bolus: evaluation with bolus and continuous infusion regimen. J Anesth. 2016;30:620–7.CrossRef
Metadata
Title
Rocuronium pharmacodynamic models for published five pharmacokinetic models: age and sex are covariates in pharmacodynamic models
Authors
Kenichi Masui
Sayaka Ishigaki
Atsuko Tomita
Hiroshi Otake
Publication date
01-10-2018
Publisher
Springer Japan
Published in
Journal of Anesthesia / Issue 5/2018
Print ISSN: 0913-8668
Electronic ISSN: 1438-8359
DOI
https://doi.org/10.1007/s00540-018-2543-3

Other articles of this Issue 5/2018

Journal of Anesthesia 5/2018 Go to the issue